Nanobiotix SA at HC Wainwright Investment Conference - New York Transcript
Greetings, and thanks for joining us to have a conversation with Laurent Levy, CEO of Nanobiotix. Nanobiotix is developing a radio enhancer, NBTXR3, which is hafnium oxide nanoparticles that can induce radiotherapy upon injecting into the tumor. The drug has received CE mark in 2019. Recently the company forged a global co-development and co-commercialization agreement with Janssen Pharmaceuticals.
To learn more about the drug, the co-development agreement, and the clinical development strategy, I welcome Laurent to the fireside chat. Laurent, glad to see you and appreciate you accepting our invitation to talk to our audience.
Questions & Answers
So Laurent, when you started the company back in 20 years ago, so what was the problem that you were trying to solve? And since you have -- since then, what sort of achievements has the company made?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
